Researchers have developed a one-time injectable drug that produces lasting reductions in LDL cholesterol without requiring ongoing doses. A clinical trial demonstrated a 62% drop in LDL levels, the "bad" cholesterol linked to heart disease and stroke.

The drug works through gene therapy, targeting the liver's ability to process cholesterol. Instead of taking daily pills, patients receive a single injection that modifies how their body handles LDL production at the genetic level. This approach differs fundamentally from statins, the current standard treatment that requires lifelong daily use.

The trial results represent a breakthrough for patients with familial hypercholesterolemia, a genetic condition causing dangerously high cholesterol levels from birth. These individuals often struggle to control their cholesterol despite maximum doses of existing medications. The one-time treatment offers an alternative path for managing a condition that affects roughly 1 in 250 to 1 in 500 people.

Beyond genetic hypercholesterolemia, researchers explore whether this therapy could help the broader population with elevated cholesterol. If approved for wider use, it could reshape how doctors treat cardiovascular risk. Eliminating the burden of daily medication adherence removes a significant barrier to cholesterol management, particularly among patients who skip doses or stop taking statins due to side effects.

The drug still requires regulatory approval before reaching patients. Standard pharmaceutical development timelines mean several years likely pass before widespread availability. Safety data from longer-term follow-up studies also needs evaluation, though early results appear promising.

Cholesterol management remains central to preventing heart disease, the leading cause of death in the United States. Current medications like statins lower LDL but don't eliminate it entirely, and roughly half of patients stop taking them within a year. A permanent solution addresses both the medical and behavioral challenges that plague traditional approaches.

This development reflects how gene therapy moves from theoretical promise into clinical